Loading...
Market
What will be Monopar's revenue growth rate for FY 2024?
2
Monopar Therapeutics•Alexion Pharmaceuticals•AstraZeneca Rare Disease•Wilson Disease•Monopar•ALXN•Phase•Alexion•AstraZeneca
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Monopar Therapeutics' annual financial reports
Story
Monopar Therapeutics Stock Surges 137% After Agreement for ALXN-1840, Phase 3 Drug for Wilson Disease
Oct 24, 2024, 04:08 PM
Monopar Therapeutics (NASDAQ: MNPR) has announced a significant agreement with Alexion Pharmaceuticals and AstraZeneca Rare Disease for its late-stage drug candidate targeting Wilson Disease. Following the announcement, Monopar's stock surged approximately 137%, prompting a trading halt due to volatility. The agreement grants Monopar an exclusive worldwide license to ALXN-1840, a drug candidate for Wilson Disease that has already completed a Phase 3 clinical trial. The stock was up about 20% ahead of Thursday's trading session, reflecting investor optimism regarding the potential of the drug and the strategic collaboration with Alexion and AstraZeneca.
View original story
Similar markets
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%
Above 30% • 25%
20%-30% • 25%
10%-20% • 25%
Below 10% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 25% • 25%
26% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
10-15% • 25%
0-5% • 25%
5-10% • 25%
15% or more • 25%
Below 50% • 25%
50% to 100% • 25%
100% to 150% • 25%
Above 150% • 25%